| Product Name | MF | CAS | Details |
|---|
| ALK/EGFR-IN-1 | 2730430-08-5 | Details |
| Lp-PLA2-IN-16 | C22H17F5N4O3 | 1865780-73-9 | Details |
| IPG7236 | C23H31N3O3S | 2756350-91-9 | Details |
| PIKfyve-IN-2 | 2245319-25-7 | Details |
| Lp-PLA2-IN-15 | C22H17F5N4O3 | 1865796-11-7 | Details |
| Bivamelagon | C35H53ClN4O4 | 2641595-54-0 | Details |
| P2X3 antagonist 38 | 2545974-71-6 | Details |
| DRI-C25441 | C31H21N3O6 | 2101765-83-5 | Details |
| Lp-PLA2-IN-13 | C22H17F5N4O4 | 2756855-62-4 | Details |
| SOS1/KRAS-IN-1 | 2836330-34-6 | Details |
| CXCR4-IN-1 | 2304750-48-7 | Details |
| TLR7/8 agonist 8 | C24H30N6O | 2649170-16-9 | Details |
| DGKζ-IN-1 | C27H25F3N6O2S | 2660218-70-0 | Details |
| Protein kinase inhibitor 5 | C29H31F2N7O | 2278204-94-5 | Details |
| PCSK9-IN-16 | C16H20N6O2S3 | 2455424-51-6 | Details |
| JAK-IN-28 | 2445500-22-9 | Details |
| CDK7-IN-22 | C22H25F3N6 | 2173190-60-6 | Details |
| PCSK9-IN-17 | 2455424-72-1 | Details |
| HPK1 antagonist-1 | C28H29FN6O2 | 2628489-56-3 | Details |
| HDAC ligand-1 | C7H8N2O | 34840-28-3 | Details |
| Z1078601926 | C14H19FN2O | 1493256-85-1 | Details |
| PHD2-IN-1 | 2768219-28-7 | Details |
| RIP1 kinase inhibitor 6 | 2428401-62-9 | Details |
| RIP1 kinase inhibitor 5 | C13H17F2NO2 | 2428422-17-5 | Details |
| UPCDC30766 | 2152623-68-0 | Details |
| RIP1 kinase inhibitor 4 | 2919836-00-1 | Details |
| BDM91514 | 2892824-90-5 | Details |
| Lp-PLA2-IN-12 | 2637485-14-2 | Details |
| Antitubercular agent-39 | 1357796-08-7 | Details |
| RIP1 kinase inhibitor 7 | 2428401-23-2 | Details |
| ETAP | 2575731-47-2 | Details |
| Antibacterial agent 141 | 2930013-56-0 | Details |
| JAK-IN-30 | 2891469-99-9 | Details |
| S-Gem | C13H15F2N3O6S2 | 2169925-98-6 | Details |
| Bromodomain inhibitor-12 (edisylate) | 2010124-27-1 | Details |
| Bromodomain inhibitor-12 | 2010124-06-6 | Details |
| K-80001 | 242800-40-4 | Details |
| SORT-PGRN interaction inhibitor 3 | C15H19Cl2NO3 | 2691846-87-2 | Details |
| PB131 | C16H16FN3O2 | 2924425-63-6 | Details |
| Tubulin polymerization-IN-42 | 2640220-51-3 | Details |
| MmpL3-IN-2 | 2944458-65-3 | Details |
| MEK-IN-6 hydrate | 2845153-35-5 | Details |
| THRβ receptor agonist-1 | 2403721-00-4 | Details |
| TNF-α-IN-10 | 2247720-56-3 | Details |
| ROCK-IN-6 | C19H19N5O8S | 2489328-74-5 | Details |
| IRE1α kinase-IN-8 | 1338933-29-1 | Details |
| Antifungal agent 59 | 2422019-96-1 | Details |
| VMAT2-IN-2 tosylate | C27H36F3NO6S | 2608770-12-1 | Details |
| DRI-C21041 | C30H21N3O7S | 2101765-78-8 | Details |
| IRAK4-IN-28 | 2952532-92-0 | Details |
| Mcl-1 inhibitor 13 | 2445466-06-6 | Details |
| ALK2-IN-5 | C24H32N8O2 | 2414149-20-3 | Details |
| STAT6-IN-3 | C32H35IN3O7P | 371919-80-1 | Details |
| SOS1-IN-16 | 2930763-85-0 | Details |
| MEK-IN-6 | C18H20FN3O4S | 2845151-86-0 | Details |
| PAD4-IN-2 | 2642327-52-2 | Details |
| BBDDL2059 | 2691174-27-1 | Details |
| SHP2-IN-14 | 2673400-91-2 | Details |
| FKBP51F67V-selective antagonist Ligand2 | 1680228-76-5 | Details |
| DSO-5a | 2195411-63-1 | Details |
| FGFR-IN-11 | 2658488-68-5 | Details |
| IRE1α kinase-IN-9 | 1338933-30-4 | Details |
| MAT2A-IN-12 | C20H17NO3 | 631897-75-1 | Details |
| PI3Kγ inhibitor 7 | 2575863-25-9 | Details |
| Antiproliferative agent-30 | 2713553-88-7 | Details |
| Lp-PLA2-IN-14 | 2756855-66-8 | Details |
| FD2056 | 2685870-87-3 | Details |
| Antiproliferative agent-34 | 2910858-34-1 | Details |
| URAT1&XO inhibitor 1 | C20H13N5O3S | 2669726-78-5 | Details |
| Antitumor agent-101 | 2848632-52-8 | Details |
| URAT1&XO inhibitor 2 | C14H12BrNO3 | 1239488-96-0 | Details |
| TLR8 agonist 6 | C19H29N7O2 | 2616605-55-9 | Details |
| Mosnodenvir | 2890688-86-3 | Details |
| SLMP53-2 | C26H22N2O2 | 1826116-38-4 | Details |
| Anticancer agent 147 | 2241283-11-2 | Details |
| PROTAC α-synuclein degrader 5 | C39H41N7O10 | 2781922-42-5 | Details |
| AMPK activator 11 | 2948304-00-3 | Details |
| SARS-CoV-2-IN-57 | 1265624-68-7 | Details |
| Antiproliferative agent-32 | 2925814-05-5 | Details |
| BChE-IN-17 | C23H23BrN2O4S2 | 2425632-57-9 | Details |
| Tegeprotafib | C13H11FN2O5S | 2407610-46-0 | Details |
| ALK/EGFR-IN-3 | 2730432-72-9 | Details |
| anti-TNBC agent-3 | 2422001-25-8 | Details |
| ALK/EGFR-IN-2 | 2730432-75-2 | Details |
| E2730 | 1520073-91-9 | Details |
| AMPA receptor modulator-4 | C11H12ClFN2O2S | 2917551-59-6 | Details |
| MDM2/XIAP-IN-2 | C29H32N2O4S | 2761969-85-9 | Details |
| RET-IN-23 | C28H28FN11 | 2479961-46-9 | Details |
| Tau protein aggregation-IN-1 | C17H11BrN2O2 | 916179-45-8 | Details |
| A1/A3 AR antagonist 3 | C22H19N5O3 | 2665804-57-7 | Details |
| BET-IN-15 | C21H18F2N4O3S | 2408994-22-7 | Details |
| ATR-IN-24 | C23H26N6O2 | 2370889-43-1 | Details |
| HIV-1 inhibitor-56 | 2952530-45-7 | Details |
| SUCNR1-IN-1 | C26H22ClF3N2O4 | 2711753-52-3 | Details |
| SSI-4 | C19H21ClN4O3 | 1875084-68-6 | Details |
| TLR7/8 agonist 9 | C20H26N6O | 2649170-17-0 | Details |
| Enpp-1-IN-17 | C18H24N4O2 | 2289736-54-3 | Details |
| Bivamelagon hydrochloride | C35H54Cl2N4O4 | 2641595-55-1 | Details |
| KAT modulator-1 | C20H36O2 | 1314006-43-3 | Details |
| Product Total： Product Page： | ||||
| 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 | ||||